Evidence map›Paper›PMID 39305341›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Predicting overall survival in anaplastic thyroid cancer using machine learning approaches.

Arnavaz Hajizadeh Barfejani, Mohammadreza Rostami, Mohammad Rahimi, Hossein Sabori Far, Shahab Gholizadeh, Morteza Behjat, Aidin Tarokhian

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arnavaz Hajizadeh BarfejaniRoyal College of Surgeons in Ireland, Dublin, Ireland.
Mohammadreza RostamiXi'an Jiaotong University, Xi'an, China.
Mohammad RahimiStudent Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
Hossein Sabori FarChaloos Razi Hospital, Mazandaran, Iran.
Shahab GholizadehChaloos Razi Hospital, Mazandaran, Iran.
Morteza BehjatSchool of Medicine, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Aidin TarokhianMedical School, Hamadan University of Medical Sciences, Pajoohesh Blvd., Hamadan, Iran. tarokhianaidin@gmail.com.ORCID http://orcid.org/0000-0002-6168-5168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnaplastic thyroid carcinoma (ATC) is a highly aggressive and lethal thyroid cancer subtype with a poor prognosis. Recent advancements in machine learning (ML) have the potential to improve survival predictions. This study aimed to develop and validate ML models using the SEER database to predict 3-month, 6-month, and 12-month (overall survival) OS in ATC patients.

methodsClinical and demographic data for patients with ATC from the SEER database (2004-2015) were utilized. Five ML algorithms-AdaBoost, support vector machines, gradient boosting classifiers, random forests, and naive Bayes-were evaluated. The data were split into training and testing sets (7:3 ratio), and the models were tuned using fivefold cross-validation. Model performance was assessed using the concordance index (C-index) and Brier score, with 95% confidence intervals reported.

resultsThe gradient boosting model achieved the greatest performance for 3-month survival (C-index: 0.8197, 95% CI 0.7682-0.8689; Brier score: 0.1802), and the AdaBoost model achieved the greatest performance in 6-month survival (C-index: 0.8473, 95% CI 0.7979-0.8933; Brier score: 0.1775). The SVC model showed superior performance for 12-month survival (C-index: 0.8347, 95% CI 0.7866-0.8816; Brier score: 0.1476). Using SHAP with a gradient boosting model, the top five features affecting 6-month OS were identified: surgery, the presence of stage IVC, radiation, chemotherapy, and tumor size. Treatment improved survival, while higher stages reduced survival, with smaller tumors generally linked to better outcomes.

conclusionML algorithms can accurately predict short-term survival in ATC patients. These models can potentially guide clinical decision-making and individualized treatment strategies.

Indexed as

Machine LearningThyroid Carcinoma, AnaplasticThyroid NeoplasmsAgedAlgorithmsFemaleHumansMaleMiddle AgedPrognosisSEER ProgramSurvival RateUnited StatesAIAnaplastic thyroid cancerMachine learningSurvivalThyroid cancer

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.